NCT07621627

Brief Summary

Cross-over study. Patients treated with peritoneal dialysis are investigated twice with a single 4h dwell study: once with Bicarbonate-Lactate solution as buffer (Physioneal TM) and once with conventional lactate PD solution (Dianeal TM). Radioidinated human serum albumin is used as a volume marker to assess ultrafiltration and frequent dialysis and blood sampling to assess peritneal transport of solutes and pH changes.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
7

participants targeted

Target at below P25 for phase_3

Timeline
Completed

Started Sep 1997

Shorter than P25 for phase_3

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 9, 1997

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 13, 1997

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 13, 1997

Completed
28.5 years until next milestone

First Submitted

Initial submission to the registry

May 12, 2026

Completed
21 days until next milestone

First Posted

Study publicly available on registry

June 2, 2026

Completed
Last Updated

June 4, 2026

Status Verified

May 1, 2026

Enrollment Period

2 months

First QC Date

May 12, 2026

Last Update Submit

June 2, 2026

Conditions

Keywords

peritoneal dialysisPeritoneal dialysis solutionperitoneal solute transportacid-base balance

Outcome Measures

Primary Outcomes (1)

  • Difference in net ultrafiltration (ml)

    Assessment of fluid transport during a PD dwell. Intraperitoenal volume changes during the 4 hour dwells will be assesed from dilution of the added volume marker with correction for absorption of the marker. Amount of marker remaining in the drained fluid after four hours will be subratcted from the initial added amount to calculate amount of marker absorbed during the dwell. Residual volumes before and after the dwell can also be calculated from dilution of the marker. This makes it possible to calculate the intraperitoneal volume of time curve during the dwell and net ultrafiltration (=net fluid removal). To simplify, the intraperitoneal volume (ml) at 240 minutes of the dwell minus the intraperitoneal volume after infusion of the dialysis fluid.

    4 hours

Secondary Outcomes (3)

  • Changes to acid-base homeostasis

    4 hours

  • Differences in small solute transport

    4 hours

  • Differences in protein transport

    4 hours

Study Arms (2)

Bicarbonate lactate solution investigatd first

EXPERIMENTAL

The patients were studied with the bicarbonate-lactate solution the first study day and with conventional lactate.based solution on a later day.

Drug: Test of peritoneal transport with bicarbonate-lactate buffered peritoneal dialysis solution and lactate solutin

Lactate solution investigated first

EXPERIMENTAL

The patients were studied with the conventional lactate.based solution the first study day and with bicarbonate-lactate solution on a later day.

Drug: Test of peritoneal transport with bicarbonate-lactate buffered peritoneal dialysis solution and lactate solutin

Interventions

All patients were studied twice with a 4-h dwell study (one peritoneal dialysis dwell) about 7 days apart. The two arms represent different order of the used periteonal dialysis fluid for the two dwell studies.

Bicarbonate lactate solution investigatd firstLactate solution investigated first

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • patient treated with peritoneal dialysis in a clinically stable condition

You may not qualify if:

  • none

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Research unit, renal medicine

Stockholm, S-141 86, Sweden

Location

MeSH Terms

Conditions

Kidney Failure, Chronic

Condition Hierarchy (Ancestors)

Renal Insufficiency, ChronicRenal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Design

Study Type
interventional
Phase
phase 3
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
CROSSOVER
Model Details: Patients are studied twice for four hours on different days, once with conventional PD solution at the time of the study, once with bicarbonate-lactate solution.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate professor, MD, PhD

Study Record Dates

First Submitted

May 12, 2026

First Posted

June 2, 2026

Study Start

September 9, 1997

Primary Completion

November 13, 1997

Study Completion

November 13, 1997

Last Updated

June 4, 2026

Record last verified: 2026-05

Locations